Company: LIMN
Filing Date: 2025-08-13
Form Type: 424B3
Source: 0001410578-25-001746
Chunk: 48

Company: Liminatus Pharma, Inc.
Filing Date: 2025-08-13
Form: 424B3
Chunk 48
---
 the initiatives that may be adopted in the future. The continuing

33

efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare and/or impose price controls may adversely affect:

| ● | the demand for our products after obtaining any regulatory approval; |

| ● | Liminatus’s ability to receive or set a price that it believes is fair for its products; |

| ● | Liminatus’s ability to generate revenue and achieve or maintain profitability; |

| ● | the level of taxes that Liminatus is required to pay; and |

| ● | the availability of capital. |

Liminatus expects that the ACA, as well as other healthcare reform measures that may be adopted in the future, may result in additional reductions in Medicare and other healthcare funding, more rigorous coverage criteria, lower reimbursement and new payment methodologies. This could lower the price that Liminatus receives for any approved product. Any denial in coverage or reduction in reimbursement from Medicare or other government-funded programs may result in a similar denial or reduction in payments from private payors, which may prevent Liminatus from being able to generate sufficient revenue, attain profitability or commercialize its product candidates, if approved. Liminatus’s employees, independent contractors, consultants, commercial partners and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements. Liminatus is exposed to the risk of fraud, misconduct or other illegal activity by its employees, independent contractors, consultants, commercial partners and vendors. Misconduct by these parties could include intentional, reckless and negligent conduct that fails to:

| ● | comply with the laws of the FDA, EMA and other comparable foreign regulatory authorities; |

| ● | provide true, complete and accurate information to the FDA, EMA and other comparable foreign regulatory authorities; |

| ● | comply with manufacturing standards Liminatus has established; |

| ● | comply with healthcare fraud and abuse laws in the United States and similar foreign fraudulent misconduct laws; or |

| ● | report financial information or data accurately or to disclose unauthorized activities to Liminatus. |

If Liminatus obtains FDA approval of any of its product candidates and begins commercializing those products in the United States, its potential exposure under such laws will increase significantly, and its costs associated with compliance with such laws are also likely to increase. In particular, research, sales, marketing, education and other business arrangements in the healthcare industry are subject to extensive laws designed to prevent fraud,